July 15, 2026 Ref: NEPHROPLUS/SE/59

To
BSE Limited
P.J. Towers, Dalal Street,
Mumbai - 400 001
Scrip Code: 544647
Through: BSE Listing Centre

To
National Stock Exchange of India Limited
5th Floor, Exchange Plaza, Bandra (E),
Mumbai - 400 051
Scrip Symbol: NEPHROPLUS
Through: NEAPS

Sub: Intimation of allotment of Equity Shares pursuant to the Exercise of Stock Options under the NephroPlus Employees Stock Option Scheme, 2011 ("ESOP Scheme 2011")

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”), we hereby inform that the Nomination and Remuneration Committee ("**NRC**" or the "**Committee**") of the Company, by way of a circular resolution passed on July 14, 2026, has approved the allotment of 2,18,297 (Two Lakh Eighteen Thousand Two Hundred Ninety Seven only) equity shares of face value of ₹2/- each, fully paid-up, pursuant to the exercise of stock options by the eligible employees under the ESOP Scheme 2011. These equity shares shall rank pari-passu with the existing equity shares of the Company in all respects.

Consequent to the aforesaid allotment, the issued, subscribed and paid-up equity share capital of the Company has increased from ₹20,06,81,434, comprising 10,03,40,717 equity shares of face value of ₹2/- each, to ₹20,11,18,028, comprising 10,05,59,014 equity shares of face value of ₹2/- each.

The Company has obtained the in-principal approvals for listing of the aforesaid equity shares from the National Stock Exchange of India Limited vide letter no. NSE/LIST/54518 dated May 11, 2026, and from BSE Limited vide letter no. DCS/ESOP/IP/RD/062/2026-27 dated May 11, 2026.

The disclosures required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as **Annexure A**.

Further, the details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as **Annexure B**.

The aforesaid information is also being made available on the Company’s website at www.nephroplus.com.

For Nephrocare Health Services Limited
(Formerly Nephrocare Health Services Private Limited)
Kathri Kishore Digitally signed by Kathri Kishore Date: 2026.07.15 11:45:41 +05'30'
Kishore Kathri
Company Secretary and Head Legal
Membership No.: F9895

Encl: a/a

Annexure A

Sr. No.	Particulars	Remark
1	Company name and address of Registered Office	**Nephrocare Health Services Limited** (Formerly Nephrocare Health Services Private Limited) 5th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Survey No. 64, Shaikpet, Hyderabad, 500081
2	Name of the recognized Stock Exchanges on which the company's shares are listed	BSE Limited (BSE) National Stock Exchange of India Limited (NSE)
3	Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognized Stock Exchange	April 10, 2026
4	Filing Number, if any	Reference of In – Principal Approval a. NSE- NSE/LIST/54518 dated May 11, 2026 b. BSE- DCS/ESOP/IP/RD/062/2026-27 dated May 11, 2026
5	Title of the Scheme pursuant to which shares are issued, if any	NephroPlus Employees Stock Option Scheme, 2011 ("**ESOP Scheme 2011**")
6	Kind of security to be listed	Equity Shares
7	Par value of the shares	₹ 2/- each
8	Date of issue of shares	July 14, 2026
9	Number of shares issued	2,18,297 fully paid-up equity shares of Rs. 2/- each
10	Share Certificate No., if applicable	Not Applicable
11	Distinctive number of the share, if applicable	10,03,40,718 to 10,05,59,014 (both inclusive)
12	ISIN Number of the shares if issued in Demat	INE428V01029
13	Exercise price per share	Refer Annexure C
14	Premium per share	Refer Annexure C
15	Total Issued shares after this issue	10,05,59,014
16	Total Issued share capital after this issue	₹ 20,11,18,028
17	Details of any lock-in on the shares	Not Applicable
18	Date of expiry of lock-in	Not Applicable
19	Whether shares identical in all respects to existing shares if not, when will they become identical?	The equity shares allotted shall rank pari-passu and are identical in all respects with the existing equity shares including payment of dividend and other rights.
20	Details of listing fees, if payable	Not Applicable

Annexure B

Sr. No.	Particulars	Details
1.	Brief details of options granted	The present instance pertains to the allotment of 2,18,297 equity shares of Rs. 2/- each, pursuant to the exercise of options under the NephroPlus Employees Stock Option Scheme, 2011 ("**ESOP Scheme 2011**").
2.	Whether the scheme is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.	Yes
3.	Total number of shares covered by these options	The present instance pertains to the allotment of 2,18,297 equity shares of Rs. 2/- each, pursuant to the exercise of options under ESOP Scheme 2011".
4.	Pricing formula	The Exercise Price payable by an Employee upon exercise of the Options shall be as specified in the respective Grant Letter(s) issued under the ESOP Scheme, 2011 and shall be payable in accordance with the terms and conditions thereof. For details please refer Annexure C
5.	Options vested	Not Applicable.
6.	Time within which option may be exercised	
7.	Options exercised	2,18,297 options were exercised for the current allotment.
8.	Money realized by exercise of options	₹2,08,18,944.35 (Rupees Two Crore Eight Lakh Eighteen Thousand Nine Hundred Forty-Four and Thirty-Five Paise only) excluding applicable taxes.
9.	Total number of shares arising as a result of exercise of options	Each stock option granted under the ESOP Scheme 2011 originally entitled the option holder, upon exercise, to subscribe to one (1) equity share of the Company having a face value of ₹10/- each. Subsequently, pursuant to the sub-division of every equity share of face value ₹10/- each into five (5) equity shares of face value ₹2/- each, approved by the shareholders of the Company on May 26, 2025, and the subsequent bonus issue in the ratio of 1:2 (i.e., two bonus shares for every one equity share held), approved by the Board of Directors and the shareholders on the same date, the outstanding stock options were appropriately adjusted in accordance with the provisions of the ESOP Scheme 2011 and Regulation 5 of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, so as to preserve the value of the options and ensure that the employees were neither advantaged nor disadvantaged on account of such corporate actions.

		Consequently, each original stock option became exercisable into fifteen (15) equity shares of face value ₹2/- each, with the exercise price being correspondingly adjusted in accordance with the adjustment formula prescribed under the ESOP Scheme and the applicable provisions of the SBEB Regulations. Accordingly, the proposed allotment of 2,18,297 equity shares of face value ₹2/- each represents the equity shares to be issued pursuant to the valid exercise of the corresponding adjusted stock options under the ESOP Scheme.
10.	Options lapsed	Not Applicable.
11.	Variation of terms of options	Not Applicable.
12.	Brief details of significant terms	Options are granted, vested and exercised in accordance with the provisions of ESOP Scheme 2011 and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The ESOP Scheme 2011 is administered by the Nomination and Remuneration Committee of the Board of Directors of the Company. The Options granted under the ESOP Scheme 2011 vest over such period and are subject to such time-based, performance-based, business, strategic, market-based and/or other conditions as may be determined by the Nomination and Remuneration Committee at the time of grant and specified in the respective Grant Letter. Vested Options may be exercised within the exercise period specified in the respective Grant Letter. The equity shares allotted pursuant to the exercise of vested Options rank pari passu with the existing equity shares of the Company in all respects.
13.	Subsequent changes or cancellation or exercise of such options	Not applicable
14.	Diluted earnings per share pursuant to issue of equity shares on exercise of options	The diluted earnings per share shall be computed in accordance with the applicable Indian Accounting Standards (Ind AS), particularly Ind AS 33 – Earnings per Share, after giving effect to the allotment of equity shares pursuant to the exercise of Options.

Annexure C

Sr No.	Allotment Date	No. of Shares allotted	Exercise Price (in ₹)	Premium per share (in ₹)	Total Exercise money (in ₹)
1	14-07-2026	1,05,000	49.2667	47.2667	51,73,000.35
2		1,500	78.5770	76.5770	1,17,865.50
3		4,500	197.3330	195.3330	8,87,998.50
4		2,250	246.5990	244.5990	5,54,847.75
5		2,250	78.5770	76.5770	1,76,798.25
6		1,125	246.5990	244.5990	2,77,423.88
7		1,125	246.5990	244.5990	2,77,423.88
8		22,500	78.5770	76.5770	17,67,982.50
9		7,500	78.6000	76.6000	5,89,500.00
10		3,750	197.3330	195.3330	7,39,998.75
11		2,250	78.5770	76.5770	1,76,798.25
12		2,350	197.3330	195.3330	4,63,732.55
13		1,875	78.5770	76.5770	1,47,331.88
14		4,200	246.5990	244.5990	10,35,715.80
15		2,250	98.2210	96.2210	2,20,997.25
16		1,500	78.5770	76.5770	1,17,865.50
17		1,500	246.5990	244.5990	3,69,898.50
18		1,200	78.6000	76.6000	94,320.00
19		3,750	176.0250	174.0250	6,60,093.75
20		2,200	78.5767	76.5767	1,72,868.67
21		3,495	78.6000	76.6000	2,74,707.00
22		1,125	246.5990	244.5990	2,77,423.88
23		1,125	246.5990	244.5990	2,77,423.88
24		1,875	246.5990	244.5990	4,62,373.13
25		1,500	78.5770	76.5770	1,17,865.50
26		5,640	176.0250	174.0250	9,92,781.00
27		1,537	246.5990	244.5990	3,79,022.66
28		2,250	78.5770	76.5770	1,76,798.25
29		1,500	78.5770	76.5770	1,17,865.50
30		1,100	246.5990	244.5990	2,71,258.90
31		775	246.5990	244.5990	1,91,114.23
32		5,000	78.6000	76.6000	3,93,000.00
33		800	246.5990	244.5990	1,97,279.20
34		1,000	246.5990	244.5990	2,46,599.00
35		4,500	98.2210	96.2210	4,41,994.50
36		5,250	197.3330	195.3330	10,35,998.25
37		1,500	78.5770	76.5770	1,17,865.50
38		3,750	220.0300	218.0300	8,25,112.50
Total		**2,18,297**			**2,08,18,944.35**

***

Nephrocare Health Services Limited (Global Corporate Headquarters)
(Formerly Nephrocare Health Services Private Limited)
5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500 081, Telangana, India.
+91 40 4240 8039 contactus@nephroplus.com www.nephroplus.com
CIN: L85100TG2009PLC066359 | GSTIN: 36AADCN1504A1Z8 | ISD GST: 36AADCN1504A2Z7